Healthcare >> CEO Interviews >> September 14, 2018
Interview with the President, CEO, Co-Founder and Director: miRagen Therapeutics, Inc. (NASDAQ:MGEN)
William S. Marshall, Ph.D., is miRagen Therapeutics, Inc.’s President, Chief Executive Officer, Co-Founder and Director. Prior to establishing miRagen, He was Vice President of Technology and Business Development for Bioscience at Thermo Fisher Scientific. In this role, he was responsible for leading technology assessment and strategic planning for the Thermo Fisher Biosciences Division, a unit with revenues of approximately $1 billion that manufactures and supplies a wide range of products and services across the general-chemistry and life-sciences arenas. Dr. Marshall was one of the scientific founders of Dharmacon, Inc., which was acquired by Fisher Scientific International, serving as the Executive Vice President for Research and Operations and General Manager. Prior to joining Dharmacon, Dr. Marshall served in many capacities at Amgen, Inc., most recently as Associate Director of Research, Site Head for Research, and Head of the Nucleic Acid and Peptide Technology Department. In these positions, he participated in a wide variety of therapeutic development approaches throughout the drug discovery process leading to the development of clinical candidates. Dr. Marshall earned his B.S. in biochemistry from the University of Wisconsin-Madison and his Ph.D. in chemistry in the laboratory of Professor Marvin Caruthers at the University of Colorado at Boulder. He is author and co-author of over 50 research papers and 80 patents. Dr. Marshall currently serves on the board of FluoroFinder, LLC and Ribometrix. Profile
Word count: 3,188
TWST: Can you describe the company's core technology?
Dr. Marshall: We are focused on targeting a novel class of endogenous RNA targets called